San Francisco, CA, United States of America

John Thomas Cunningham


Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: John Thomas Cunningham: Innovator in Cancer Treatment

Introduction

John Thomas Cunningham is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. His work focuses on targeting specific cellular mechanisms to improve therapeutic outcomes for patients.

Latest Patents

Cunningham holds a patent for his invention titled "Phosphoribosyl pyrophosphate synthetase 2 (PRPS2) as a therapeutic target in cancer treatment." This patent outlines methods for selectively killing cancer cells by inhibiting the enzyme phosphoribosyl pyrophosphate synthetase 2 (PRPS2). The invention also includes methods for identifying candidate agents that can selectively kill neoplastic cells that are Myc-hyperactivated through the inhibition of PRPS2. This innovative approach has the potential to enhance cancer treatment strategies.

Career Highlights

Cunningham is affiliated with the University of California, where he conducts his research and develops his inventions. His work has garnered attention for its potential impact on cancer therapies, showcasing his commitment to advancing medical science.

Collaborations

Cunningham collaborates with fellow researcher Davide Ruggero, contributing to the development of innovative cancer treatment methodologies. Their partnership exemplifies the collaborative spirit of scientific research, aimed at achieving breakthroughs in healthcare.

Conclusion

John Thomas Cunningham's contributions to cancer treatment through his patented invention highlight the importance of innovation in medical research. His work continues to pave the way for new therapeutic strategies that could significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…